New study pokes holes in lung cancer: which ablation method wins?
NCT ID NCT06503744
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two ways to destroy early-stage lung cancer tumors using heat (radiofrequency ablation) without surgery. One method goes through the chest wall, the other through the airways using a bronchoscope. Researchers will check which approach is safer and more effective at completely killing the tumor, with 110 participants being followed for up to a year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 110 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2024
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age greater than 18 years. 2. Primary peripheral lung cancer diagnosed by pathology and pre-procedure staging examination suggesting clinical stage T1N0M0, stage IA (including postoperative new and multiple primary). 3. The proposed ablation lesion was evaluated for feasibility of CT and bronchoscopy-guided ablation treatment. 4. Consent to initial ablation therapy is given after assessment of unsuitability for surgery or refusal of surgery and signed informed consent form. Exclusion Criteria: 1. Patients with platelets \<50×109/L, severe bleeding tendency and coagulation dysfunction that cannot be corrected in the short term. 2. Patients with severe pulmonary fibrosis and pulmonary arterial hypertension. 3. Infectious and radioactive inflammation around the lesion, skin infection at the puncture site that is not well controlled, systemic infection, high fever \>38.5°C. 4. Patients with severe hepatic, renal, cardiac, pulmonary and cerebral insufficiency, severe anaemia, dehydration and serious disorders of nutritional metabolism that cannot be corrected or improved in the short term. 5. Those with poorly controlled malignant pleural effusions. 6. Anticoagulation therapy and/or anti-platelet drugs (except dabigatran, rivaroxaban and other new oral anticoagulants) have not been discontinued more than 5\~7d before ablation. 7. Eastern Cooperative Oncology Group (ECOG) score \>2. 8. Combination of other tumours with extensive metastases and an expected survival of \<6 months. 9. Patients with episodic psychosis. 10. Patients with implanted electronic devices (e.g. pacemakers or defibrillators). 11. Pregnant women, or patients with a pregnancy planned during the study period. 12. Have participated or are participating in other clinical studies within the last 30 days. 13. Any other condition that the investigator considers inappropriate for participation in this study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lung cancer stage IA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, 200030, China